DRTS Valuation
Alpha Tau Medical Ltd
$
3.300
- Overview
- Forecast
- Valuation
DRTS Relative Valuation
DRTS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DRTS is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for DRTS's competitors is 129.06, providing a benchmark for relative valuation. Alpha Tau Medical Ltd Corp (DRTS) exhibits a P/S ratio of 771.16, which is 497.52% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
JMSB
John Marshall Bancorp Inc
17.500
USD
0.00%
TG
Tredegar Corp
8.300
USD
+1.10%
WTI
W&T Offshore Inc
1.410
USD
-2.76%
LNKB
LINKBANCORP Inc
7.120
USD
-0.97%
NREF
Nexpoint Real Estate Finance Inc
14.920
USD
-1.32%
OSUR
OraSure Technologies Inc
2.600
USD
-7.14%
CPS
Cooper-Standard Holdings Inc
22.400
USD
-5.21%
BYON
Beyond Inc
6.200
USD
-6.63%
FVR
FrontView REIT Inc
11.270
USD
-2.00%
INVZ
Innoviz Technologies Ltd
0.921
USD
-5.24%
FAQ
Is Alpha Tau Medical Ltd (DRTS) currently overvalued or undervalued?
Alpha Tau Medical Ltd (DRTS) is now in the Overvalued zone, suggesting that its current forward PS ratio of 771.16 is considered Overvalued compared with the five-year average of 304.48. The fair price of Alpha Tau Medical Ltd (DRTS) is between 1.24 to 2.33 according to relative valuation methord. Compared to the current price of 3.30 USD , Alpha Tau Medical Ltd is Overvalued By 41.35% .
What is Alpha Tau Medical Ltd (DRTS) fair value?
How does DRTS's valuation metrics compare to the industry average?
What is the current P/B ratio for Alpha Tau Medical Ltd (DRTS) as of May 21 2025?
What is the current FCF Yield for Alpha Tau Medical Ltd (DRTS) as of May 21 2025?
What is the current Forward P/E ratio for Alpha Tau Medical Ltd (DRTS) as of May 21 2025?